Other Transaction Agreement HQ08452490048

The Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement to The Public Health Co Group Inc. for prototype development addressing national threat infections, with a ceiling value of $12,347,549.71 and an award date of April 26, 2024. The effort, titled "Prototype Development for Attributing National Threat Infections Direct Origin to Evaluation (WASTEWATER-ANTI-DOTE)," focuses on wastewater-based attribution and detection capabilities. Performance is based in...

This is a firm fixed price purchase order (contract) awarded by the Defense Health Agency to Biobot Analytics Inc., a self-certified small disadvantaged business, to provide SARS-COV-2 analytical services. The contract is valued at $129,600.00 and has a completion date of March 13, 2025. The original solicitation was set aside for total small business and required the contractor to provide ribonucleic acid (RNA) virus detection using quantitative polymerase chain reaction (qPCR) and reverse...

This is a $5,840,883.00 contract awarded by the Joint Program Executive Office for Chemical and Biological Defense to RTX BBN Technologies, Inc. (doing business as BBN Technologies) for the development of a prototype system for attributing the origins of national threat infections to wastewater samples. The contract is an Other Transaction Agreement with no set-aside designation, and the work will be performed in Cambridge, Massachusetts. BBN Technologies is a subsidiary of Raytheon Technologies...

The Defense Health Agency awarded a $1.299 million definitive contract to Godx Inc., a minority-owned small disadvantaged business, for rapid identification of pathogens from water and wastewater on September 15, 2025, under a total small business set-aside. The contract is firm fixed price with an ultimate completion date of January 14, 2028. Place of performance is Madison, Wisconsin. The originating solicitation addresses rapid pathogen detection capabilities to support military force...

This contract was awarded by the Joint PEO Chemical and Biological Defense, a defense agency, to Advanced Technology International (ATI), a public service nonprofit organization, to conduct research and development into medical, pharmaceutical, and diagnostic technologies to enhance the mission effectiveness of military personnel. The contract is an Other Transaction Agreement with a ceiling value of $10,000,000,000.00 and a completion date of April 7, 2036. ATI frequently partners with...

This federal contract award, valued at $1,666,327.15, was issued by the Defense Health Agency (DHA) to the Medical Technology Enterprise Consortium (MTEC), a nonprofit organization that serves as a medical technology accelerator for the Department of Defense. The contract, designated as an Other Transaction Order, is part of a larger $3,466,511.50 Other Transaction Indefinite Delivery Vehicle (IDV) agreement between MTEC and the DHA. The purpose of the contract is for MTEC to develop...

The U.S. Department of Defense's Joint Program Executive Office for Chemical and Biological Defense awarded a $29,929,031.81 Other Transaction Agreement to Just-Evotec Biologics, Inc. to produce monoclonal antibody (mAb) product countermeasures against COVID-19. The contract, awarded on January 15, 2021, has an ultimate completion date of June 30, 2022 and is not set aside for any special business categories. Just-Evotec Biologics, Inc. is a for-profit, foreign-owned manufacturer of goods.

<p>The Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement to Icon Government And Public Health Solutions, Inc. on April 28, 2020, with a ceiling value of $78,461,505.99 to conduct COVID-19 Phase I, II, and III clinical trials in support of COVID-19 vaccines and therapeutics, as well as a Botulinum Phase II clinical trial. This OTA operates outside the FAR framework. Performance occurs in Hinckley, Ohio, with an ultimate completion date of June 30, 2026.</p>

This federal contract award to Lumen Bioscience, Inc. is for the PANACEA project, an Other Transaction Agreement (OTA) with a ceiling value of $11,137,568.00. The award was made on May 2, 2023 by the Joint PEO Chemical and Biological Defense, a Defense agency, and has an ultimate completion date of December 15, 2024. The contract is focused on providing biological research and development services, including developing biologic drugs and therapeutic delivery platforms. Lumen Bioscience...

This is a delivery order awarded by the Joint PEO Chemical and Biological Defense, a U.S. Department of Defense agency, to Leidos, Inc. It provides one year of &quot;CRITICAL FUNCTION&quot; - NEW REQUIREMENT ACWA TEST EQUIPMENT (ATE) SUPPORT. The contract is a cost-plus-fixed-fee vehicle issued under the $900 million Program and Integration Support V (PAIS V) indefinite-delivery, indefinite-quantity contract. The order has a ceiling value of $5,758,908.00 and does not utilize a set-aside. As the...